Testotoxicosis proved by immunohistochemical analysis and successfully treated with cyproterone acetate.
We present a case of testotoxicosis diagnosed on the basis of immunohistochemical investigation of the testis. The patient was treated with the antiandrogen cyproterone acetate at a dose of 70-130 mg/m2/day. Clinical and biochemical features are consistent with the diagnosis of testotoxicosis. The long-term experience with cyproterone acetate had been generally satisfactory. There are, to our knowledge, no reports on cyproterone acetate treatment of testotoxicosis.
Itoh
K
K
Department of Urology, Yamagata University School of Medicine, Japan.
Nakada
T
T
Kubota
Y
Y
Suzuki
H
H
Ishigooka
M
M
Izumi
T
T
D000367:Age Factors; D000726:Androgen Antagonists / Q000008:administration & dosage*; D002675:Child, Preschool; D017373:Cyproterone Acetate / Q000008:administration & dosage*; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone; D006801:Humans; D007150:Immunohistochemistry; D007985:Leydig Cells / Q000473:pathology; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D011629:Puberty, Precocious / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D013737:Testis / Q000737:chemistry* / Q000473:pathology; D013739:Testosterone / Q000032:analysis* / Q000097:blood
D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D017373:Cyproterone Acetate; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone